Physician profile
Jun Xu
NPI 1497010391
$15,332.09
in general payments reported to CMS, 2019-2025
44 companies · $3,454 in 2025
The $3,454 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $666 · 2021: $881 · 2022: $1,590 · 2023: $3,967 · 2024: $4,047 · 2025: $3,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,468.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,478.05 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,796.74 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Amgen INC. | $1,567.33 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $1,351.04 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $944.41 | 2020-2024 | Xarelto |
| Shockwave Medical, INC | $634.04 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $562.27 | 2023-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $507.64 | 2023-2025 | Rexulti |
| Madrigal Pharmaceuticals | $458.38 | 2024-2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $413.20 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Ardelyx, INC. | $353.61 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.87 | 2020-2024 | Jardiance |
| Ironwood Pharmaceuticals, INC | $336.07 | 2020-2023 | Linzess |
| Teva Pharmaceuticals USA, INC. | $318.57 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amarin Pharma, INC. | $258.08 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.